Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buspirone Hydrochloride

FDA-approved product (tablet, oral), marketed as Bucapsol, Buspar, Buspirone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Buspirone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Azaspirodecanedione derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli41.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buspirone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buspirone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Buspirone for Anxiety in Autistic Youth

    NCT07439042 · start 2026-09

    Registered record
    Registry ID
    NCT07439042
    Conditions
    Anxiety; Autism Spectrum Disorder
    Interventions
    buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2029-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety; Autism Spectrum Disorder
    Interventionbuspirone; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders

    NCT03432065 · start 2024-12

    Registered record
    Registry ID
    NCT03432065
    Conditions
    Autism Spectrum Disorder; Anxiety
    Interventions
    Buspirone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-12
    Completion
    2025-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder; Anxiety
    InterventionBuspirone
    PhasePhase 2
    Registry statusWithdrawn

  • Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

    NCT06321341 · start 2024-01-24

    Registered record
    Registry ID
    NCT06321341
    Conditions
    Vertigo; Autonomic Dysfunction
    Interventions
    Vespireit; Arlevert
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-01-24
    Completion
    2026-12-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVertigo; Autonomic Dysfunction
    InterventionVespireit; Arlevert
    PhasePhase 4
    Registry statusRecruiting

  • Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal

    NCT03954483 · start 2023-10-16

    Registered record
    Registry ID
    NCT03954483
    Conditions
    Anxiety
    Interventions
    Buspirone 10 Mg Oral Tablet; Triazolam 0.25 MG Oral Tablet; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-10-16
    Completion
    2027-10-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    InterventionBuspirone 10 Mg Oral Tablet; Triazolam 0.25 MG Oral Tablet; Placebo oral tablet
    PhaseNot applicable
    Registry statusRecruiting

  • Evaluating Buspirone to Treat Opioid Withdrawal

    NCT05511909 · start 2022-12-15

    Registered record
    Registry ID
    NCT05511909
    Conditions
    Opioid Use Disorder; Opioid Withdrawal; Opioid Craving; Anxiety
    Interventions
    Buspirone; Lofexidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-15
    Completion
    2027-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Withdrawal; Opioid Craving; Anxiety
    InterventionBuspirone; Lofexidine; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Serotonin-receptor Agonism in Reward Processing

    NCT05357547 · start 2022-05-13

    Registered record
    Registry ID
    NCT05357547
    Conditions
    Anhedonia
    Interventions
    Buspirone 20mg; Placebo comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-05-13
    Completion
    2023-04-18
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnhedonia
    InterventionBuspirone 20mg; Placebo comparator
    PhasePhase 2
    Registry statusCompleted

  • Effects of Buspirone Combined With Clozapine

    NCT06906224 · start 2022-05-01

    Registered record
    Registry ID
    NCT06906224
    Conditions
    Schizophrenia
    Interventions
    Control group (clozapine, placebo); Low-dose group (buspirone tablets, clozapine); High-dose group (buspirone tablets, clozapine)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2022-05-01
    Completion
    2023-12-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionControl group (clozapine, placebo); Low-dose group (buspirone tablets, clozapine); High-dose group (buspirone tablets, clozapine)
    PhaseEarly phase 1
    Registry statusCompleted

  • Buspirone Treatment of Anxiety in Williams Syndrome

    NCT04807517 · start 2021-08-01

    Registered record
    Registry ID
    NCT04807517
    Conditions
    Williams Syndrome; Anxiety
    Interventions
    Buspirone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-01
    Completion
    2023-09-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWilliams Syndrome; Anxiety
    InterventionBuspirone
    PhasePhase 4
    Registry statusCompleted

  • Buspirone for Weak or Absent Esophageal Peristalsis

    NCT05629325 · start 2021-07-06

    Registered record
    Registry ID
    NCT05629325
    Conditions
    Dysphagia, Esophageal
    Interventions
    Buspirone Hydrochloride 10 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-07-06
    Completion
    2024-09-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDysphagia, Esophageal
    InterventionBuspirone Hydrochloride 10 MG; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)

    NCT04770454 · start 2021-02-08

    Registered record
    Registry ID
    NCT04770454
    Conditions
    Depressive Disorder, Major; Anxiety Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-02-08
    Completion
    2023-03-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major; Anxiety Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

    NCT04118387 · start 2021-01-07

    Registered record
    Registry ID
    NCT04118387
    Conditions
    Sleep Disordered Breathing; Able Bodied
    Interventions
    Acetazolamide + supplemental oxygen + PAP therapy; Zolpidem + PAP therapy; Buspirone + PAP therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-01-07
    Completion
    2027-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disordered Breathing; Able Bodied
    InterventionAcetazolamide + supplemental oxygen + PAP therapy; Zolpidem + PAP therapy; Buspirone + PAP therapy
    PhasePhase 4
    Registry statusRecruiting

  • Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

    NCT04458324 · start 2020-12-22

    Registered record
    Registry ID
    NCT04458324
    Conditions
    Spinal Cord Injuries
    Interventions
    Buspirone Hydrochloride; Buspirone placebo; Noninvasive Ventilation (NIV); Sham Non-invasive ventilation (NIV); Functional Electrical Stimulation Row Training (FESRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-22
    Completion
    2027-07-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries
    InterventionBuspirone Hydrochloride; Buspirone placebo; Noninvasive Ventilation (NIV); Sham Non-invasive ventilation (NIV) +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Improving Ventilatory Capacity in Those With Chronic High Level SCI

    NCT05041322 · start 2020-11-29

    Registered record
    Registry ID
    NCT05041322
    Conditions
    Spinal Cord Injuries
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-29
    Completion
    2024-11-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries
    InterventionBuspirone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Buspirone and Melatonin for Depression Following Traumatic Brain Injury

    NCT04400266 · start 2020-08-01

    Registered record
    Registry ID
    NCT04400266
    Conditions
    Depression; Brain Injuries, Traumatic
    Interventions
    Buspirone; Mealatonin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-08-01
    Completion
    2028-07-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Brain Injuries, Traumatic
    InterventionBuspirone; Mealatonin
    PhasePhase 4
    Registry statusRecruiting

  • Transformation of Paralysis to Stepping

    NCT04105114 · start 2019-09-30

    Registered record
    Registry ID
    NCT04105114
    Conditions
    Spinal Cord Injuries
    Interventions
    Buspirone; Non-invasive Spinal Cord Stimulation; Overground stepping; Gravity Neutral Device; Body Weight Supported Treadmill Training; Rolling Walker
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2019-09-30
    Completion
    2027-12-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries
    InterventionBuspirone; Non-invasive Spinal Cord Stimulation; Overground stepping; Gravity Neutral Device +2 more
    PhaseEarly phase 1
    Registry statusActive not recruiting